Pluri
Expands cells for therapies, manufacturing and cultivated-food ventures.
Something off on this page? Send us feedback.
Profile
Builds cell-expansion systems for contract development and manufacturing, agricultural collaborations, therapeutic candidates and majority-owned food-tech ventures. Revenue has come primarily from CDMO services and AgTech fees, while commercialization spans several early-stage businesses.
Uses a proprietary cell-expansion platform to grow human or plant cells in controlled environments and deploys it across several commercial and development lines. PluriCDMO provides cell-therapy process-development and manufacturing services, while agricultural collaborations generate fees. Cellav is developing regenerative-aesthetics products, and the therapeutic portfolio includes the PLX-PAD and PLX-R18 product candidates.
Extends the platform through Ever After Foods for cultivated meat and fish infrastructure, Kokomodo for cacao ingredients, and Coffeesai for cultivated coffee. Headquarters, research and manufacturing are in Haifa, with commercial and collaboration activity spanning Asia, Europe, the United States and the United Kingdom. Therapeutic candidates require regulatory authorization; food ventures depend on scale-up, economics and food-regulatory processes; core operations remain concentrated in Israel.
Company facts
Key statistics
Year to date −49.8% · Average volume (30d) 25.7K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| May 14, 2026Q3 FY26 | −$0.66 | −$0.55 | +16.7% | $655.0K | $167.0K | −74.5% | −0.88% |
| Feb 12, 2026Q2 FY26 | −$0.65 | −$0.71 | −9.2% | $638.0K | $198.0K | −69.0% | +0.28% |
| Nov 12, 2025Q1 FY26 | −$0.74 | −$0.65 | +12.2% | $638.0K | $316.0K | −50.5% | −6.07% |
| Sep 17, 2025Q4 FY25 | −$0.65 | −$2.62 | −303.1% | $638.0K | $398.0K | −37.6% | −4.26% |
Financial highlights
| 12 quarters | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $185.0K | $427.0K | $398.0K | $316.0K | $198.0K | $167.0K | |
| Gross profit | $111.0K | $136.0K | $207.0K | −$15.0K | −$43.0K | $56.0K | |
| Operating income | −$5.0M | −$5.4M | −$6.6M | −$6.4M | −$6.5M | −$6.6M | |
| Net income | −$3.0M | −$6.1M | −$7.6M | −$5.9M | −$6.5M | −$6.2M | |
| Diluted EPS | −$0.53 | −$1.14 | −$0.96 | −$0.65 | −$0.71 | −$0.55 | |
| Gross margin | 60.0% | 31.9% | 52.0% | -4.7% | -21.7% | 33.5% | |
| Operating margin | -2,679.5% | -1,264.6% | -1,663.6% | -2,009.5% | -3,285.9% | -3,922.2% |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $234.0K · FY23 $287.0K · FY24 $326.0K · FY25 $1.3M
Balance sheet, Mar 31, 2026Cash & short-term investments $9.5M · Total debt $33.6M · Total assets $26.1M · Shareholders' equity −$18.6M
Dividends
No dividends on record.
Ownership
Shares outstanding 10.79M · Float 6.17M · 57.2% free float
A Form 4 total here can count shares the filer formally disclaims — an award voted by proxy, for instance — which the holder's own Schedule 13D/G excludes, so where the two disagree the schedule's smaller figure is used.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Alexandre Weinstein | 4.35M | 35.00% | 13D | Jul 1, 2026 |
| Merchant Adventure Fund, L.P. | 1.28M | 18.20% | 13G | Apr 16, 2025 |
| Yaky Yanay · director, officer: Chief Executive Officer | 484.9K | 4.49% | Form 4 | Dec 8, 2025 |
| Alexandre Weinstein Manieu · director, 10 percent owner: | 190.8K | 1.77% | Form 4 | Aug 24, 2026 |
| Zami Aberman · director | 144.2K | 1.34% | Form 4 | Dec 8, 2025 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Steakholder Foods (ADR)
Alternative-protein production technology for cultivated-meat partnerships.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Pluri | $1.53 | +2.00% | $16.5M | — | — | 15.3 | −60.9% |
| Steakholder Foods (ADR) | $2.96 | −1.66% | $2.1M | — | — | — | — |